Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
BackgroundExtramedullary (EM) lesions are common in multiple myeloma (MM) and are often related to the poor prognosis of MM but are scarcely understood.MethodsIn this retrospective study, the baseline characteristics of 357 newly diagnosed patients with extramedullary multiple myeloma (EMM) and thei...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.668099/full |
id |
doaj-a679fde311f9405fac7ca4846341b2a3 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
JingSong He XiaoYan Yue DongHua He Yi Zhao Yang Yang GaoFeng Zheng Enfan Zhang XiaoYan Han WenJun Wu Li Yang Jing Chen Zhen Cai Zhen Cai Zhen Cai |
spellingShingle |
JingSong He XiaoYan Yue DongHua He Yi Zhao Yang Yang GaoFeng Zheng Enfan Zhang XiaoYan Han WenJun Wu Li Yang Jing Chen Zhen Cai Zhen Cai Zhen Cai Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma Frontiers in Oncology extramedullary multiple myeloma extramedullary-bone related extramedullary extraosseous PFS OS |
author_facet |
JingSong He XiaoYan Yue DongHua He Yi Zhao Yang Yang GaoFeng Zheng Enfan Zhang XiaoYan Han WenJun Wu Li Yang Jing Chen Zhen Cai Zhen Cai Zhen Cai |
author_sort |
JingSong He |
title |
Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma |
title_short |
Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma |
title_full |
Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma |
title_fullStr |
Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma |
title_full_unstemmed |
Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma |
title_sort |
multiple extramedullary-bone related and/or extramedullary extraosseous are independent poor prognostic factors in patients with newly diagnosed multiple myeloma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-07-01 |
description |
BackgroundExtramedullary (EM) lesions are common in multiple myeloma (MM) and are often related to the poor prognosis of MM but are scarcely understood.MethodsIn this retrospective study, the baseline characteristics of 357 newly diagnosed patients with extramedullary multiple myeloma (EMM) and their impact on the prognosis were analyzed. All patients received first-line treatment with bortezomib-based regimen.ResultsThe overall incidence rate of EM was 22.4%, and the detection rate of PET/CT was significantly higher than other imaging methods (P = 0.015). The cohorts consisted of 10 cases of extramedullary extraosseous (EME) and 70 cases of extramedullary-bone related (EMB), including 53 cases with single site involvement (one case with EME) and 27 cases with multiple sites (>1 site) involvement (nine cases with EME). EMM patients had high levels of hemoglobin (Hgb, ≥10 g/dl) and serum lactate dehydrogenase (LDH, >245u/L) and are inclined to early-stage revised international staging system (R-ISS). Compared to patients without EM, those with EMM had worse progression-free survival (PFS) (P = 0.014) and overall survival (OS) (P = 0.032). In addition, patients without EM and those with a single site of EMB had similar PFS and OS, while patients with multiple sites of EMB or EME and multiple sites of EMB with EME had poor PFS and OS. Multivariate analysis confirmed that multiple sites of EMB and/or EME were independent prognostic predictors affecting PFS and OS in newly diagnosed MM patients.ConclusionsThis study suggested that among patients treated with bortezomib-based regimens, multiple sites of EMB and/or EME are independent poor prognostic factors for newly diagnosed MM patients, while a single site of EMB does not affect the survival of newly diagnosed MM patients. Thus, these findings could be used as a reference for the study of EMM patients in the new drug era, but prospective clinical studies are needed to provide evidence-based data for the diagnosis and treatment of EMM. |
topic |
extramedullary multiple myeloma extramedullary-bone related extramedullary extraosseous PFS OS |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.668099/full |
work_keys_str_mv |
AT jingsonghe multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT xiaoyanyue multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT donghuahe multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT yizhao multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT yangyang multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT gaofengzheng multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT enfanzhang multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT xiaoyanhan multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT wenjunwu multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT liyang multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT jingchen multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT zhencai multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT zhencai multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma AT zhencai multipleextramedullarybonerelatedandorextramedullaryextraosseousareindependentpoorprognosticfactorsinpatientswithnewlydiagnosedmultiplemyeloma |
_version_ |
1721315638752837632 |
spelling |
doaj-a679fde311f9405fac7ca4846341b2a32021-07-07T12:53:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-07-011110.3389/fonc.2021.668099668099Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple MyelomaJingSong He0XiaoYan Yue1DongHua He2Yi Zhao3Yang Yang4GaoFeng Zheng5Enfan Zhang6XiaoYan Han7WenJun Wu8Li Yang9Jing Chen10Zhen Cai11Zhen Cai12Zhen Cai13Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaInstitute of Hematology, Zhejiang University, Hangzhou, ChinaZhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou, ChinaBackgroundExtramedullary (EM) lesions are common in multiple myeloma (MM) and are often related to the poor prognosis of MM but are scarcely understood.MethodsIn this retrospective study, the baseline characteristics of 357 newly diagnosed patients with extramedullary multiple myeloma (EMM) and their impact on the prognosis were analyzed. All patients received first-line treatment with bortezomib-based regimen.ResultsThe overall incidence rate of EM was 22.4%, and the detection rate of PET/CT was significantly higher than other imaging methods (P = 0.015). The cohorts consisted of 10 cases of extramedullary extraosseous (EME) and 70 cases of extramedullary-bone related (EMB), including 53 cases with single site involvement (one case with EME) and 27 cases with multiple sites (>1 site) involvement (nine cases with EME). EMM patients had high levels of hemoglobin (Hgb, ≥10 g/dl) and serum lactate dehydrogenase (LDH, >245u/L) and are inclined to early-stage revised international staging system (R-ISS). Compared to patients without EM, those with EMM had worse progression-free survival (PFS) (P = 0.014) and overall survival (OS) (P = 0.032). In addition, patients without EM and those with a single site of EMB had similar PFS and OS, while patients with multiple sites of EMB or EME and multiple sites of EMB with EME had poor PFS and OS. Multivariate analysis confirmed that multiple sites of EMB and/or EME were independent prognostic predictors affecting PFS and OS in newly diagnosed MM patients.ConclusionsThis study suggested that among patients treated with bortezomib-based regimens, multiple sites of EMB and/or EME are independent poor prognostic factors for newly diagnosed MM patients, while a single site of EMB does not affect the survival of newly diagnosed MM patients. Thus, these findings could be used as a reference for the study of EMM patients in the new drug era, but prospective clinical studies are needed to provide evidence-based data for the diagnosis and treatment of EMM.https://www.frontiersin.org/articles/10.3389/fonc.2021.668099/fullextramedullary multiple myelomaextramedullary-bone relatedextramedullary extraosseousPFSOS |